ViewRay, Inc. (NASDAQ:VRAY) released its earnings results on Monday. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.02, Morningstar.com reports. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. During the same period in the previous year, the company posted ($0.32) earnings per share. ViewRay’s revenue was up 133.3% on a year-over-year basis.

ViewRay (NASDAQ:VRAY) traded up 10.10% during mid-day trading on Tuesday, reaching $5.78. 1,475,995 shares of the company traded hands. The firm’s market cap is $331.67 million. ViewRay has a one year low of $2.64 and a one year high of $10.39. The stock’s 50-day moving average price is $6.03 and its 200-day moving average price is $6.22.

ILLEGAL ACTIVITY WARNING: “ViewRay, Inc. (NASDAQ:VRAY) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/viewray-inc-nasdaqvray-issues-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.

A number of hedge funds and other institutional investors have recently modified their holdings of VRAY. Highbridge Capital Management LLC purchased a new position in shares of ViewRay during the first quarter worth about $167,000. Boston Financial Mangement LLC purchased a new position in shares of ViewRay during the first quarter worth about $170,000. HighTower Advisors LLC purchased a new position in shares of ViewRay during the first quarter worth about $170,000. Wells Fargo & Company MN purchased a new position in shares of ViewRay during the first quarter worth about $177,000. Finally, UBS Group AG boosted its position in shares of ViewRay by 447.7% in the first quarter. UBS Group AG now owns 22,479 shares of the company’s stock worth $192,000 after buying an additional 18,375 shares in the last quarter. Hedge funds and other institutional investors own 49.56% of the company’s stock.

Several analysts recently commented on VRAY shares. Cantor Fitzgerald started coverage on shares of ViewRay in a research note on Thursday, June 29th. They set an “overweight” rating and a $10.00 target price for the company. Northland Securities reissued a “buy” rating and set a $7.00 target price on shares of ViewRay in a research note on Tuesday, May 16th. Aegis reissued a “buy” rating and set a $11.00 target price on shares of ViewRay in a research note on Tuesday, May 16th. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of ViewRay in a research note on Wednesday, May 17th. Finally, ValuEngine raised shares of ViewRay from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $9.50.

About ViewRay

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Earnings History for ViewRay (NASDAQ:VRAY)

Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with MarketBeat.com's FREE daily email newsletter.